Kimberly-Clark (KMB) Q3 2026 earnings review
Kimberly-Clark profit rises on lower taxes, but core sales shrink
Kimberly-Clark closed its purchase of Tylenol maker Kenvue just as its own diaper and tissue sales shrank. Sales from businesses owned a year ago fell 1.3% after false social-media rumors in China hurt Huggies demand and North American promotions lowered prices. Profit per share from continuing operations excluding one-offs jumped 17%, but lower tax and interest bills drove that gain while gross margin fell. Chief executive Mike Hsu kept the full-year outlook in place, though a slower market leaves only about 0.7% underlying sales growth for the year by our math.
| Sales from businesses owned a year ago | -1.3% from a year ago (-2.7 percentage points from China) |
|---|---|
| Gross margin, excluding one-offs | 35.5% -1.3 percentage points from a year ago |
| Profit per share from continuing operations, excluding one-offs | $1.70 +17.2% from a year ago (on lower tax and interest) |
| Full-year standalone outlook | Reaffirmed category growth baseline slowed to 1.7% from 2.0% |
⚖️ Verdict: 🔴 Bearish
The standalone story got worse because the Chinese boycott bit deeper than the 2-point second-half pace management indicated last quarter, and North American price cuts and a delayed product launch erased the margin cushion once tariff refunds ended. On the other side, the newly acquired Kenvue brands are turning around faster than they were a year ago, with 70% now growing.
The question now is whether combining with Kenvue creates a stronger consumer-health leader or just adds a second turnaround in skin and oral care while diluting shareholders into 2027. If Hsu's store-level fixes work, early cost savings will cover the brand investments; if not, pruning product lines will drag on combined sales next year. Management's first combined 2027 outlook in February will provide the test.
🐂 Bull Case
Kenvue Acquisition Closes With 70% of Brands Growing
"The completion of our Kenvue transaction earlier this week marks a defining moment in the 154 year history of Kimberly-Clark," chief executive Mike Hsu said. Kenvue — the maker of Tylenol, Neutrogena and Listerine — closed its sale to Kimberly-Clark on November 2. The deal nearly doubles the company's size, but it also requires issuing roughly 280 million shares and taking on Kenvue's debt.
Hsu told analysts that Kenvue's sales from businesses owned a year ago grew 3% in the third quarter, led by Tylenol, Zyrtec, Nicorette and a 30% year-to-date jump in Rogaine hair treatment. Reviewing Kenvue's monthly brand performance, Hsu noted that "for a scorecard that looked 100% red this time last year, Nelson, I think you would agree, I think when we had our review last Thursday, it was 70% green".
That turnaround matters because Kenvue's problems look fixable through better store execution rather than broken brands, and Hsu now expects to beat the $1.9 billion cost-savings target. Still, finance chief Nelson Urdaneta confirmed that 2027 profit per share excluding one-offs will fall by a mid-single-digit percentage against standalone Kimberly-Clark, partly because the buyer does not strip out acquisition-related intangible write-downs.
What to watch: the combined 2027 financial plan in February. A smaller profit drop than the mid-single-digit forecast would show that early Kenvue cost cuts are running ahead of schedule.
Cost Savings Cushion a $250 Million Inflation Bill
Kimberly-Clark uses its 2024 Transformation Initiative — a multi-year factory and supply-chain overhaul — to fund brand marketing and offset rising raw-material and trucking costs. Urdaneta said full-year cost inflation now stands at $250 million, up $50 million from August because North American spot trucking rates rose.
In the third quarter, factory efficiency savings reached 5.8% of the cost of making its products, or 6.1% across the first nine months. The company also cut marketing, research and general overhead excluding one-offs by 1.1 percentage points of sales by our math, which kept operating profit excluding one-offs within 0.9% of last year at $677 million despite the China hit.
What to watch: fourth-quarter operating profit excluding one-offs. By our math, hitting the middle of the full-year outlook requires roughly 11.5% growth in the final quarter as third-quarter cost actions take hold.
Positives this quarter didn't test
One long-term product project from last quarter got no update in the third-quarter release or on the call, as the Kenvue closing took over the agenda.
- Alternative natural fiber platform: management gave no figures on committed capital, pilot-plant capacity in the US Southwest, or unit costs against wood pulp; the February investor event is the next chance for detail.
🐻 Bear Case
China Diaper Boycott Cut Deeper Than Planned
False social-media claims about Huggies diaper quality in China hit sales late in the second quarter, when management estimated the fallout would trim second-half underlying sales by about 2 percentage points. On the call, Hsu noted that "the Chinese authorities refuted the false allegations and they declared that Huggies were safe".
Even with that official clearance, the third-quarter damage exceeded the 2-point pace, and overall category growth across the company's markets slowed from 2.0% to 1.7%.
- Company-wide underlying sales: down 1.3%, including a 2.7-percentage-point hit from China (up 1.4% without it, by our math)
- International Personal Care underlying sales: down 4.6%, dragged down 7.7 percentage points by China
- International Personal Care operating profit: $144 million, down 32.7%, with China accounting for 16.8 points of the drop
This matters because government clearance came too late to save the November 11 shopping festival in China, so Urdaneta expects fourth-quarter Chinese sales to stay weak while the company spends to rebuild trust.
What to watch: International Personal Care underlying sales growth in the fourth quarter. A smaller drag than this quarter's 7.7 percentage points would show Chinese parents are returning to Huggies.
North America Discounts and Delays Stall Sales
North America is Kimberly-Clark's largest division, bringing in $2.7 billion of third-quarter sales. Hsu said the division's health is solid, pointing to a 2.0% rise in shipments and market-share gains of 0.2 percentage points in consumer and professional tissue.
Yet underlying sales in the region edged up only 0.4% because net prices fell 1.8% on heavier store promotions. Three internal and customer issues also held the division back: retailers cut their warehouse stock for a 1.3-point drag, lost shelf space at club stores took off about 1 point, and management had to "postpone a major new product launch" until early next year because a new machine "wasn't putting out the quality that we wanted".
What to watch: North America net pricing in the fourth quarter. Management expects full-year pricing to finish nearly even with last year after sitting 0.8% lower through nine months, which requires fourth-quarter price increases to stick.
Taxes and Interest Drove the 17% Profit Jump
Kimberly-Clark highlighted a 17.2% rise in third-quarter profit per share from continuing operations excluding one-offs, to $1.70, as proof of its operating model. Beneath that headline figure, the business earned less from selling its products than it did a year ago.
Gross margin excluding one-offs fell 1.3 percentage points to 35.5% as the cost of making products rose by 1.3 points of sales, driven by "unfavorable pricing net of cost inflation and supply chain related investments, partially offset by strong productivity savings". Last quarter's one-time tariff refund did not repeat, and operating profit excluding one-offs dipped 0.9%.
The entire per-share profit gain came below the operating line. Net interest costs dropped by $27 million to $32 million, and the tax rate excluding one-offs fell 7 percentage points to 19.5% on a "combination of transitory impacts in the prior year from the One Big Beautiful Bill Act ("OBBBA") and benefits in the current year from certain tax initiatives".
What to watch: gross margin excluding one-offs in the fourth quarter. A second quarter of contraction would show that factory savings cannot cover lower prices and higher trucking bills without one-time tariff refunds.
Risks this quarter didn't answer
Two standing balance-sheet and target questions received no new figures in the third-quarter release.
- Post-merger debt and share dilution: the release ends on September 30 before the Kenvue close; the full-year report will show combined debt and when buybacks resume after issuing ~280 million shares.
- Decade-end margin targets: management went silent for a third straight quarter on its 40% gross margin and 18–20% operating margin goals; the February investor event should clarify if Kenvue resets them.
👓 Other Themes
Tissue Venture Sale Nets a $1.4 Billion Gain
On July 1, Kimberly-Clark completed the transfer of its International Family Care and Professional tissue unit into Arbex, a joint venture with Brazilian pulp maker Suzano. The exit produced a $1.4 billion pre-tax gain in discontinued operations, lifting reported net income to $1.8 billion. In continuing operations, Kimberly-Clark booked a $20 million net loss for its share of Arbex's start-up and restructuring charges.
💲 Other KPIs
Free cash flow — cash from operations minus capital spending — rose 28.7% from a year ago across the first nine months, and rose 33.7% to $492 million in the third quarter alone by our math. Operating cash flow climbed to $2.4 billion, aided by $444 million from a long-term license agreement, outpacing a 40.2% rise in factory spending.
Total debt from continuing operations fell 9.4% from $7.17 billion at the end of 2025, while cash nearly tripled to $1.87 billion after the July tissue-venture sale. By our math, net debt dropped 28.8% to $4.62 billion on September 30, ahead of the debt assumed when Kenvue closed in November.
Kimberly-Clark's share of profit from joint ventures fell 37.0% from $46 million a year ago, reversing gains earlier in the year and leaving the nine-month total unchanged at $137 million. A $20 million net loss from the new Arbex tissue venture — which carried $38 million of after-tax restructuring charges — offset currency-aided gains in Mexico.
🔮 Guidance
Unchanged in formula, lower in implied growth. The plan still calls for underlying sales to trail category growth by "approximately 100 basis points below its weighted average category growth" due to China, and now puts category growth at 1.7% instead of 2.0%. By our math, that points to 0.7% full-year growth and requires a 1.9% rebound in the fourth quarter against an easy 0.8% North America comparison.
Unchanged. The standalone plan still calls for operating profit excluding one-offs to rise about 4% to 6% before currency effects. Because operating profit excluding one-offs is up 3.0% through nine months, hitting a 5% full-year middle of the range requires roughly 11.5% growth in the fourth quarter by our math, supported by third-quarter cost cuts.
Unchanged. Standalone profit per share from continuing operations excluding one-offs is still set to grow about 7% to 9% before currency. After rising 8.5% to $5.10 across the first nine months, the middle of the full-year range leaves roughly 5.6% growth for the fourth quarter by our math.
Unchanged. Total profit per share excluding one-offs is still set to dip 1% to 3% because the international tissue unit left the company on July 1. With nine-month profit per share up 2.1% to $5.79, a 2% full-year drop leaves about $1.59 for the fourth quarter by our math — down 14.5% from $1.86 a year ago.
❓ Key Questions
How big is the China diaper business in dollars?
The boycott took 7.7 percentage points off International Personal Care sales and 16.8% off its profit this quarter, and the fourth quarter will stay weak. Without the dollar base, investors cannot size the 2027 recovery when the comparison eases.
What are the combined margin targets after buying Kenvue?
Management has not mentioned its pre-2030 goals of a 40% gross margin and an 18–20% operating margin for three straight quarters. Adding Kenvue's higher gross margins and intangible write-downs changes the base.
How much will Kenvue skin and oral care resets cost?
Chief executive Mike Hsu said Kenvue's skin care and Listerine oral care lines are still shrinking and need product-line cleanups and higher ad spending in 2027. Investors need the size of that spending against the $1.9 billion cost-savings plan.
What is the capital budget for the plant-fiber factory?
After calling its non-wood fiber technology a major platform last quarter, management did not mention it in the third-quarter materials. Nine-month capital spending is already up 40% to $1.04 billion.